By Arno Schuetze
FRANKFURT, Oct 26 (Reuters) - German diagnostics firm Munich Leukemia Laboratory (MLL) has been put up for sale by its founders as they seek to lock in high prices for healthcare assets, sources close to the matter said.
The owners, led by Torsten Haferlach, have asked Goldman Sachs GS.N to find a buyer for the company which employs around 200 staff and specialises in leukaemia diagnostics and research, the three sources said.
MLL generates annual earnings before interest, tax, depreciation and amortisation of around 40 million euros ($47 million) and may be valued at 11-12 times that, in line with valuations of other labs groups, they said.
The company has already sent out first information packages to prospective bidders, they added.
Several private equity firms are studying the dossier and weighing the company's revenue growth against factors such as the regulatory risk of potential price caps and the key-person-risk of MLL potentially facing difficulties should co-founders and managers - Torsten and Claudia Haferlach as well as Wolfgang Kern - decide to leave the company.
MLL and Goldman Sachs declined to comment.
($1 = 0.8465 euros)
(Reporting by Arno Schuetze; Editing by Susan Fenton)
((firstname.lastname@example.org; +49 30220133648;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.